SciBase

SciBase
About Us
Contacts
Change country

Follow us:
Share:
Subscribe:

About Us

SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase’s products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase’s technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden.

Contacts

Pia Renaudin
pia.renaudin@scibase.com

Notice to extraordinary general meeting in Scibase Holding AB (publ)

Mon, Apr 08, 2024 08:30 CET

Shareholders of SciBase Holding AB (publ), reg. no. 556773-4768 (the "Company"), are hereby summoned to an extraordinary general meeting to be held on 13 May 2024 at 09.00 CEST at Advokatfirman Schjødt, Hamngatan 27, in Stockholm. The registration to the meeting will open at 08.30 CEST.This notice is a translation of a Swedish notice and in case of any deviations between the language versions, the Swedish version shall prevail. Right to participate and notice of participation A shareholder who wishes to participate at the extraordinary general meeting must: (i) be recorded in the

There are no items matching the current filter

There are no more items matching the current filter

About Us

Contacts

Links

Notice to extraordinary general meeting in Scibase Holding AB (publ)

Subscribe

Media

Youtube